TipRanks
Faeth Therapeutics (DE:4070)
FRANKFURT:4070
Germany Market
4070
Faeth Therapeutics
RESEARCH TOOLSreports

Faeth Therapeutics (4070) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

4070 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Faeth
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4070 Stock 12 Month Forecast

Average Price Target

€50.29
▲(77.08% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Faeth Therapeutics in the last 3 months. The average price target is €50.29 with a high forecast of €61.08 and a low forecast of €44.50. The average price target represents a 77.08% change from the last price of €28.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","62":"€62","19.25":"€19.25","33.5":"€33.5","47.75":"€47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61.0798923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€61.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.29175547818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€50.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.50106439,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€44.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,19.25,33.5,47.75,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,31.28306863846154,33.766137276923075,36.249205915384614,38.73227455384615,41.21534319230769,43.69841183076923,46.18148046923077,48.66454910769231,51.14761774615385,53.63068638461539,56.113755023076926,58.596823661538465,{"y":61.0798923,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,30.45321195986014,32.10642391972028,33.75963587958042,35.41284783944056,37.0660597993007,38.71927175916084,40.37248371902098,42.02569567888112,43.678907638741265,45.3321195986014,46.98533155846154,48.63854351832168,{"y":50.29175547818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,30.007774183846156,31.215548367692307,32.42332255153846,33.63109673538462,34.83887091923077,36.046645103076926,37.25441928692308,38.462193470769236,39.66996765461539,40.87774183846154,42.085516022307694,43.29329020615385,{"y":44.50106439,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€61.08Average Price Target€50.29Lowest Price Target€44.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DE:4070
Bradley Canino
Guggenheim
Guggenheim
€61.08
Buy
115.07%
Upside
Initiated
09/15/26
Faeth Therapeutics initiated with a Buy at GuggenheimFaeth Therapeutics initiated with a Buy at Guggenheim
Lucid Capital Analyst forecast on DE:4070
Dev Prasad
Lucid Capital
Lucid Capital
€51.48
Buy
81.27%
Upside
Initiated
09/14/26
Faeth Therapeutics assumed with a Buy at Lucid CapitalFaeth Therapeutics assumed with a Buy at Lucid Capital
BTIG Analyst forecast on DE:4070
Jeet Mukherjee
BTIG
BTIG
€47.99
Buy
68.98%
Upside
Reiterated
09/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:4070
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH) and Novartis (NYSE: NVS)
Needham Analyst forecast on DE:4070
Gil Blum
Needham
Needham
€48.86
Buy
72.06%
Upside
Initiated
08/21/26
Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target
H.C. Wainwright Analyst forecast on DE:4070
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€52.35
Buy
84.35%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Faeth, Maintains $60 Price Target Ahead of Phase 2 Readouts
Oppenheimer Analyst forecast on DE:4070
Jay Olson
Oppenheimer
Oppenheimer
€52.35
Buy
84.35%
Upside
Reiterated
08/05/26
Oppenheimer Keeps Their Buy Rating on Faeth Therapeutics (FTH)
JonesTrading Analyst forecast on DE:4070
Boris Peaker
JonesTrading
JonesTrading
€47.99
Buy
68.98%
Upside
Initiated
08/04/26
Faeth Therapeutics initiated with a Buy at JonesResearchFaeth Therapeutics initiated with a Buy at JonesResearch
Raymond James Analyst forecast on DE:4070
Sean McCutcheon
Raymond James
Raymond James
€48.86
Buy
72.06%
Upside
Initiated
07/31/26
Faeth Therapeutics initiated with an Outperform at Raymond JamesFaeth Therapeutics initiated with an Outperform at Raymond James
Citizens JMP Analyst forecast on DE:4070
Silvan Turkcan
Citizens JMP
Citizens JMP
€44.5
Buy
56.69%
Upside
Initiated
07/20/26
Faeth Therapeutics initiated with an Outperform at CitizensFaeth Therapeutics initiated with an Outperform at Citizens
Citi Analyst forecast on DE:4070
Geoff Meacham
Citi
Citi
€47.99
Buy
68.98%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Intuitive Surgical (NASDAQ: ISRG) and Faeth Therapeutics (NASDAQ: FTH)
Robert W. Baird Analyst forecast on DE:4070
Jack Allen
Robert W. Baird
Robert W. Baird
€49.74
Buy
75.13%
Upside
Initiated
06/26/26
Faeth Therapeutics initiated with an Outperform at BairdFaeth Therapeutics initiated with an Outperform at Baird
Cantor Fitzgerald Analyst forecast on DE:4070
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DE:4070
Bradley Canino
Guggenheim
Guggenheim
€61.08
Buy
115.07%
Upside
Initiated
09/15/26
Faeth Therapeutics initiated with a Buy at GuggenheimFaeth Therapeutics initiated with a Buy at Guggenheim
Lucid Capital Analyst forecast on DE:4070
Dev Prasad
Lucid Capital
Lucid Capital
€51.48
Buy
81.27%
Upside
Initiated
09/14/26
Faeth Therapeutics assumed with a Buy at Lucid CapitalFaeth Therapeutics assumed with a Buy at Lucid Capital
BTIG Analyst forecast on DE:4070
Jeet Mukherjee
BTIG
BTIG
€47.99
Buy
68.98%
Upside
Reiterated
09/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:4070
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH) and Novartis (NYSE: NVS)
Needham Analyst forecast on DE:4070
Gil Blum
Needham
Needham
€48.86
Buy
72.06%
Upside
Initiated
08/21/26
Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target
H.C. Wainwright Analyst forecast on DE:4070
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€52.35
Buy
84.35%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Faeth, Maintains $60 Price Target Ahead of Phase 2 Readouts
Oppenheimer Analyst forecast on DE:4070
Jay Olson
Oppenheimer
Oppenheimer
€52.35
Buy
84.35%
Upside
Reiterated
08/05/26
Oppenheimer Keeps Their Buy Rating on Faeth Therapeutics (FTH)
JonesTrading Analyst forecast on DE:4070
Boris Peaker
JonesTrading
JonesTrading
€47.99
Buy
68.98%
Upside
Initiated
08/04/26
Faeth Therapeutics initiated with a Buy at JonesResearchFaeth Therapeutics initiated with a Buy at JonesResearch
Raymond James Analyst forecast on DE:4070
Sean McCutcheon
Raymond James
Raymond James
€48.86
Buy
72.06%
Upside
Initiated
07/31/26
Faeth Therapeutics initiated with an Outperform at Raymond JamesFaeth Therapeutics initiated with an Outperform at Raymond James
Citizens JMP Analyst forecast on DE:4070
Silvan Turkcan
Citizens JMP
Citizens JMP
€44.5
Buy
56.69%
Upside
Initiated
07/20/26
Faeth Therapeutics initiated with an Outperform at CitizensFaeth Therapeutics initiated with an Outperform at Citizens
Citi Analyst forecast on DE:4070
Geoff Meacham
Citi
Citi
€47.99
Buy
68.98%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Intuitive Surgical (NASDAQ: ISRG) and Faeth Therapeutics (NASDAQ: FTH)
Robert W. Baird Analyst forecast on DE:4070
Jack Allen
Robert W. Baird
Robert W. Baird
€49.74
Buy
75.13%
Upside
Initiated
06/26/26
Faeth Therapeutics initiated with an Outperform at BairdFaeth Therapeutics initiated with an Outperform at Baird
Cantor Fitzgerald Analyst forecast on DE:4070
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
ZVRAZevra Therapeutics
IMUXImmunic
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Faeth Therapeutics

3 Months
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+119.53%
Copying Geoff Meacham's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +119.53% per trade.
1 Year
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+113.87%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +113.87% per trade.
2 Years
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+113.87%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +113.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4070 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
2
7
13
17
14
Buy
1
2
2
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
9
15
18
16
In the current month, 4070 has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4070 average Analyst price target in the past 3 months is 50.29.
Each month's total comprises the sum of three months' worth of ratings.

4070 Financial Forecast

4070 Earnings Forecast

Next quarter’s earnings estimate for 4070 is -€0.68 with a range of -€1.51 to -€0.50. The previous quarter’s EPS was -€2.45. 4070 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4070 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4070 is -€0.68 with a range of -€1.51 to -€0.50. The previous quarter’s EPS was -€2.45. 4070 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4070 has Performed in-line its overall industry.
No data currently available

4070 Sales Forecast

Next quarter’s sales forecast for 4070 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4070 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4070 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4070 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4070 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4070 has Performed in-line its overall industry.

4070 Stock Forecast FAQ

What is DE:4070’s average 12-month price target, according to analysts?
Based on analyst ratings, Faeth Therapeutics’s 12-month average price target is 50.29.
    What is DE:4070’s upside potential, based on the analysts’ average price target?
    Faeth Therapeutics has 77.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Faeth Therapeutics a Buy, Sell or Hold?
          Faeth Therapeutics has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Faeth Therapeutics’s share price target?
            The average share price target for Faeth Therapeutics is 50.29. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €61.08 ,and the lowest forecast is €44.50. The average share price target represents 77.08% Increase from the current price of €28.4.
              What do analysts say about Faeth Therapeutics?
              Faeth Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Faeth Therapeutics?
                To buy shares of DE:4070, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.